Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
NCT02825160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 282
Last updated 2024-08-19
Summary
This study is collecting post-marketing information on the safety and effectiveness of Ventavis under the routine clinical practice for patients with PAH
Conditions
- Hypertension, Pulmonary
Interventions
- DRUG
-
Ventavis (Iloprost, BAYQ6256)
The treatment of Ventavis should comply with the local product information
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-01
- Primary Completion
- 2023-03-31
- Completion
- 2023-09-27
Countries
- Japan
More Related Trials
-
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
NCT00250640 ·Status: COMPLETED
-
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
NCT01971450 ·Status: COMPLETED
-
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
NCT01781052 ·Status: COMPLETED
-
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
NCT03293407 ·Status: COMPLETED
-
Ventavis® Registry Protocol
NCT00902603 ·Status: TERMINATED
-
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
NCT01894035 ·Status: COMPLETED
-
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
NCT02826252 ·Status: COMPLETED
-
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
NCT01389271 ·Status: COMPLETED
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
NCT01468545 ·Status: COMPLETED
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
NCT02032836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT00109681 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
NCT03556020 ·Status: TERMINATED ·Phase: PHASE2
-
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
NCT02576002 ·Status: COMPLETED
-
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
NCT00302211 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
NCT00453414 ·Status: WITHDRAWN ·Phase: PHASE2
-
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
NCT00467896 ·Status: TERMINATED ·Phase: PHASE2
-
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT03754660 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00452218 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension
NCT02238535 ·Status: UNKNOWN ·Phase: PHASE2
-
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
NCT02759419 ·Status: COMPLETED ·Phase: PHASE4